AHRQ Publishes New Guide on Osteoporosis Fracture Prevention Treatments
By News Staff
9/3/2008
Fracture Prevention Treatments for Postmenopausal Women with Osteoporosis reviews a wide range of treatments, such as bisphosphonates, selective estrogen receptor modulators, hormonal medications, calcium and vitamin D. It also outlines dosage and pricing information for these products.
In its "Clinical Bottom Line" section, the guide briefly recaps the relative effectiveness of these products, offering a "level of confidence" rating for their efficacy in preventing specific types of fractures. For example, the guide says with a high level of confidence that some bisphosphonates and estrogen prevent hip and other nonvertebral fractures, whereas raloxifene, estrogen, teriparatide and most bisphosphonates prevent vertebral fractures.
The guide then analyzes various treatment approaches and gives suggestions on possible nonmedical treatments to improve bone health, including changes to diet and adherence to an exercise regimen. It also gives recommendations for daily intake of calcium and vitamin D.
Also included in the guide is information to consider when selecting a treatment approach. One key component of the selection process is possible barriers to adherence, including mode of administration, dosing regimens and cost. For example, weekly users of bisphosphonates have higher rates of adherence than daily users. The guide also advises physicians to consider the risk of adverse events. For example, it recommends avoiding the use of bisphosphonates in women with a history of serious gastrointestinal disease and avoiding zoledronic acid in women who are at high risk for atrial fibrillation.
The possible adverse effects of the various treatments are covered in some detail. Side effects of some of the drugs used to prevent osteoporotic fractures can include gastrointestinal difficulties (e.g., acid reflux, nausea, vomiting, heartburn, ulcers, bleeding), atrial fibrillation, musculoskeletal pain and osteonecrosis of the jaw.
In addition, the guide contains an entire section on hormonal medications, with a special focus on their possible side effects. These include stroke, breast cancer and other breast problems, gynecologic issues, and osteosarcoma.
NIH Panel Calls for Broader Access to TOL, VBAC
FDA Misses Target for Monitoring Antipsychotic Drug Use
ACIP Makes New Flu, Pneumococcal Vaccine Recommendations
NIH Consensus Development Conference to Address VBAC Issues
FDA Requires New Label Warnings for LABAs
NY, NJ Mumps Outbreak Affects More than 1,500
Study: Patients, Physicians Don't Always Agree on Key Health Concerns
Sanofi Shortens Shelf Life of Some H1N1 Vaccine Doses
Merck Resumes Distribution of Hib Vaccine
Lancet Retracts Controversial Study Linking MMR Vaccine, Autism
Download 2010 Shots Schedules for Smartphones, Handheld Devices
USPSTF Updates Screening Recs for Childhood, Teen Obesity
FPs' Training Critical to Haiti Disaster Response
Sibutramine Use Contraindicated in Patients With CVD, Says FDA
ACP Guideline: Assess Osteoporosis Risk for Older Men, Get DXA for Those at Increased Risk
Further Research Needed on Screening Tests
(6/4/2008)
FDA Warns of Potential Side Effect of Bisphosphonate Use
(1/9/2008)
Study Findings Highlight Need for Caution in Prescribing Newer Drugs
Alendronate, Thiazolidinediones Are Focus
(5/16/2008)
More From AAFP
familydoctor.org: Osteoporosis in Women: Keeping Your Bones Healthy and Strong
